Dr. John Zalcberg on Regorafenib in Refractory Advanced Oesophago-Gastric Cancer Patients
November 11th 2015John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about the poor prognosis of refractory advanced oesophago-gastric cancer (AOGC) patients and how regorafenib could benefit those patients.